Navigation Links
Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Date:6/2/2009

p>

Presentation Title: Weight Loss with VI-0521 (Qnexa) Stops Progression Towards Type 2 Diabetes in Obese Non-Diabetic Subjects

Abstract: 119-OR

Location: Louisiane C, Morial Convention Center

Presenter: Louis J. Aronne, MD

Date and Time: Monday, June 8, 2009, 4:30-6:30 P.M.

Session: New Treatments in Development

Presentation Title: One Year Treatment with VI-0521(Qnexa) in Type 2 Diabetes Demonstrates Continued Glycemic Improvement and Weight Loss

Abstract: 361-OR

Location: Hall E-2, Morial Convention Center

Presenter: W. Timothy Garvey, MD

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), is expected to complete phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are b
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
6. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
7. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
8. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
9. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
10. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange (WEDI), ... health IT to create efficiencies in healthcare information exchange, ... has developed an issue brief titled, “What is ... HPID Workgroup, a part of WEDI’s Strategic National HPID ... and Medicaid Services (CMS) to identify common misuse of ...
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... , July 28, 2014 ... report  "Microbial Identification Market by Products (Consumables, Instruments, Services), ... Beverages), End User (Detection, Characterization) - Global ... Microbial Identification Market is estimated at $896.5 ... reach $1,194.1 Million by 2019, growing at ...
(Date:7/28/2014)... --  Propeller Health , the FDA-cleared digital health solution ... Brad Towle as Senior Vice President, Business and ... company,s sales growth, customer acquisition and program expansion. ... past role in the development of accountable care organizations, ... time in the industry," said David Van Sickle ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... 3 .decimal, Inc. announced today that,it has ... to supply,patient-specific devices for its proton therapy facility ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090203/CLTU104LOGO ) , ... a formal agreement signed with ProCure to be,their ...
... Sleep Apnea TreatmentSAN CARLOS, Calif., Feb. 3 ... shown their patients comply with Obstructive Sleep Apnea ... average.Analysis performed in October 2008 looked at Northern ... treatment with Positive Airway Pressure beginning in early ...
... Feb. 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... Surveillance Agency, has granted BioMarin marketing approval for Naglazyme(R) ... (MPS VI)."We are very pleased to receive marketing approval ... number of affected MPS VI patients in the world," ...
Cached Biology Technology:ProCure Signs Agreement with .decimal, Inc. to Purchase Patient-Specific Devices for Its Proton Therapy Center in Oklahoma City 2SleepQuest Compliance Again Doubles Industry Average 2Naglazyme Approved by Brazil's National Health Surveillance Agency 2Naglazyme Approved by Brazil's National Health Surveillance Agency 3Naglazyme Approved by Brazil's National Health Surveillance Agency 4
(Date:7/29/2014)... of cell, including sperm, bacteria and algae, propel ... protrusions, about one-hundredth of a millimetre long, function ... Similar, shorter structures called cilia are found on ... roles such as moving liquids over the cell. ... they transport mucus and expel pathogens from our ...
(Date:7/28/2014)... the South Pole in 1911, but new research shows ... , Using data from 16 ice cores collected from ... South Pole, a group led by Joe McConnell of ... the most accurate and precise reconstruction to date of ... described in an article published today in the online ...
(Date:7/28/2014)... MA -- Fifteen years ago, MIT professor John Essigmann and ... for an HIV drug. They thought if they could induce ... weaken and eventually die out a strategy that our ... developed such a drug, which caused HIV to mutate at ... the virus from patients in a small clinical trial reported ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4
... cartilage injuries can be effectively repaired by tissue ... process concludes research led by scientists at the ... tissue engineered cartilage implanted in injured and osteoarthritic ... 12, Number 7) issue of Tissue Engineering, demonstrates ...
... that helps them recognize and isolate foreign DNA trying ... of Washington-led study in the June 8 issue of ... the Sidney Kimmel Cancer Center in San Diego, could ... bacteria. The findings may also impact the biotech industry, ...
... who are extremely obese may be underestimated as a new ... and high cholesterol than women at lower levels of obesity, ... JAMA. , Obesity diagnosis and treatment are typically based on ... calculated as weight in kilograms divided by height in meters ...
Cached Biology News:Bacteria have their own immune system protecting against outside DNA 2Higher levels of obesity associated with greater health risks 2Higher levels of obesity associated with greater health risks 3
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
... thermoactive designer enzyme that enables RT-PCR ... PCR enzyme allows reverse transcription and ... elevated temperatures (65C), which helps to ... and results in highly stringent, accurate ...
... ICE-LAP3 Mch3 Lyophilized solid. ... enzyme regulation and kinetics, cleavage of target substrates, and ... protein. One unit is defined as the ... Ac-DEVD-pNA Cat. No. 235400 per hour at 37 C ...
Request Info...
Biology Products: